Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
4 February 2021
New research, led by Melanoma Institute Australia, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.
With more than 100 million* global cases of COVID-19 infection and the pandemic ongoing, this important finding will have implications for clinical decision-making in patients being treated with immunotherapy for cancer, including melanoma.
‘Previous studies have found that cancer patients infected with COVID-19 are more likely to develop a severe form of the illness and succumb to the disease compared to those without cancer,’ said first study author Dr Aljosja Rogiers, MIA’s Cameron Medical Oncology Fellow. ‘However, it was not known if patients with cancer on immunotherapy would have an increased or decreased risk of severe COVID-19, and this warranted investigation.’
Immunotherapy works by releasing the brakes on the immune system so that it can effectively target and destroy cancer cells. Knowing that immune cells can help fight viruses too meant that it was theoretically possible that immunotherapy may be helpful in reducing the severity of COVID-19 in patients with cancer.
However, immune cells release cytokines which increases inflammation: this has the potential to make the course of a COVID-19 infection worse. This clinical conundrum needed to be investigated to help guide treatment choices for clinicians during the pandemic.
Together with their international collaborators, the researchers found that treatment with immunotherapy does not further increase the risk of developing severe COVID-19 infection in patients with cancer. Their findings were recently published in the Journal for ImmunoTherapy of Cancer.
Publication: Rogiers A, Pires da Silva I, Tentori C, Tondini CA, Grimes JM, Trager MH, Nahm S, Zubiri L, Manos M, Bowling P, Elkrief A, Papneja N, Vitale MG, Rose AAN, Borgers JSW, Roy S, Mangana J, Pimentel Muniz T, Cooksley T, Lupu J, Vaisman A, Saibil SD, Butler MO, Menzies AM, Carlino MS, Erdmann M, Berking C, Zimmer L, Schadendorf D, Pala L, Queirolo P, Posch C, Hauschild A, Dummer R, Haanen J, Blank CU, Robert C, Sullivan RJ, Ascierto PA, Miller WH Jr, Stephen Hodi F, Suijkerbuijk KPM, Reynolds KL, Rahma OE, Lorigan PC, Carvajal RD, Lo S, Mandala M, Long GV. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. J Immunother Cancer. 2021 Jan;9(1):e001931.
*Update data from Johns Hopkins Coronavirus Resource Center. COVID-19 Map. Available: https://coronavirus.jhu.edu/map.html [Accessed 3 Feb 2021].
A round of applause for a well deserved win.
A message from our CEO, Carole Renouf
Piction, Brisbane, Bahturst and Port Macquarie march to end melanoma.
Australian researchers have greater clarity on the best course of treatment for patients with advanced melanoma which has spread to the brain.
Melanoma treatment has come a long way in recent times, and the role that nurses play caring for melanoma patients has changed dramatically too.
It was a massive weekend of Melanoma Marches with six Marches in: Bendigo, Canberra, Manly, Newcastle, Bunbury and Adelaide.
Weekend two hit the ground marching with Melanoma Marches in Wollongong, Townsville, Mandurah and Western Sydney.
Melanoma Institute Australia's annual fundraising initiative is all systems go!
The reported proliferation of illegal commercial solariums is costing lives and requires urgent government intervention.
15-year-old melanoma survivor Toby Rayner will lead Mount Gambier’s march against melanoma Julie-Ann Sams knows all too well that melanoma doesn’t discriminate.
Updated guidelines defining appropriate excision margins have been published thanks to research from MIA.
Joanne and her trusty companion Frankie spend their days spreading a message of hope in hospitals, nursing homes, even prisons. It is a long way from her darkest hour facing palliative care. This is her story of hope.
Melanoma impacts more Australian teenagers and young adults than any other cancer. Dr James Wilmott, who has a young family of his own, has devoted his career to determining why these young Australians are susceptible to melanoma, and importantly, how to save them.
Melanoma Masterclass celebrates Australian luminaries who have transformed melanoma treatment worldwide
The extraordinary contribution of Australia’s most distinguished melanoma clinicians and researchers is being celebrated today.
Congratulations to Professor Richard Scolyer who was awarded the William O. Russell/Joanne Vandenberge Hill Award of Excellence in Pathology.
A Day in the Life Of... Serigne Lo, Research and BioStatistics Manager at Melanoma Institute Australia
Jay was your typical Aussie bloke – a truck driver, husband, dad and mate to many. Then he got melanoma. His cancer diagnosis turned his life upside down.
Clair faced an impossible choice – risk delivering her baby early, or delay potentially life-saving melanoma treatment
Little Madi misses her Dad. But she is determined to honour his memory and support life-saving melanoma research.